ArticleAsian Pacific journal of cancer prevention : APJCP2022
Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience.
Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute lymphoblastic leukemia (ALL) is a clonal disease that affects early lymphoid progenitors in the bone marrow. Minimal residual disease (MRD) is assessed by different methods to monitor disease kinetics after treatment.
aimto Assess MRD post-induction, at 6 and 12 months after intensive chemotherapy in adult patients with ALL. PATIENTS AND
methodsSeventy adult newly diagnosed acute lymphoblastic leukaemia patients were enrolled between July 2018 and July 2019 at the Clinical Hematology Unit, Ain Shams University hospitals, Egypt. MRD was assessed on the bone marrow samples using multi-parameter four color flow cytometry with 0.01% cut-off; below which cases are deemed MRD negative.
resultsAfter the end of induction period, 13 out of 46 patients (28%) had positive MRD. However, MRD positivity is demonstrable in 14/32(43.8%), and 10/28(35.7%) patients at 6 and 12 months; respectively. MRD positivity was significantly associated with older age group (more than 39 years) and high NCCN risk stratum with p-values <0.05. Moreover, most of MRD positive patients at 12 months of therapy were of T-ALL immunophenotype (P value 0.002). Patients with complete remission and negative MRD exhibited significantly higher overall survival when compared to patients having MRD positivity (P value 0.027).
conclusionMRD is a powerful predictor of outcome in ALL and its positivity at different time points is associated with poor prognostic factors as well as survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.